e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Intervening in allergic asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study
D. Saralaya, A. Menzies-Gow, I. Clifton, A. H. Mansur, A. Hart-Thomas, R. Niven (Bradford, London, Leeds, Birmingham, Huddersfield, Manchester, United Kingdom)
Source:
International Congress 2014 – Intervening in allergic asthma
Session:
Intervening in allergic asthma
Session type:
Poster Discussion
Number:
3480
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Saralaya, A. Menzies-Gow, I. Clifton, A. H. Mansur, A. Hart-Thomas, R. Niven (Bradford, London, Leeds, Birmingham, Huddersfield, Manchester, United Kingdom). Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study. Eur Respir J 2014; 44: Suppl. 58, 3480
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
First clinical trial of a new IgE-adsorber in allergic asthma
Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma
Year: 2015
Fungal sensitization in patients with moderate and severe asthma
Source: International Congress 2014 – Clinical allergy
Year: 2014
Five-year clinical study of children with atopic asthma
Source: International Congress 2014 – Paediatric asthma: epidemiology and risk factors
Year: 2014
Association between control of rhinitis and control of asthma as assessed by validated questionnaires
Source: International Congress 2014 – Clinical allergy
Year: 2014
Serious asthma exacerbations in a hospital setting
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
The impact of sublingual allergen-specific therapy on asthma control and quality of life
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Clinical phenotypes in asthmatic population with severe asthma
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015
Predictors factors for asthma in patients with rhinitis
Source: International Congress 2014 – Clinical allergy
Year: 2014
The impact of psychological distress on allergic rhinitis and asthma control
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Outcomes of immunotherapy of patients with COPD
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Study of psychiatric comorbidities in patients with bronchial asthma
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
Efficacy of omalizumab in Polish real-world patients
Source: International Congress 2016 – Asthma management
Year: 2016
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
Influence of maternal bronchial asthma clinical phenotype on development of allergies in children
Source: International Congress 2014 – Paediatric asthma: epidemiology and risk factors
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept